Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease.

@article{Moritz1989PhaseIS,
  title={Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease.},
  author={Thomas Moritz and Norbert Niederle and J. Baumann and Detlef May and Erhard Kurschel and Reinhard Osieka and Joachim Kempeni and Erich Schlick and Carl Gottfried Schmidt},
  journal={Cancer immunology, immunotherapy : CII},
  year={1989},
  volume={29 2},
  pages={144-50}
}
A phase I study with recombinant human tumor necrosis factor alpha (rhuTNF-alpha; Knoll AG, Ludwigshafen, FRG) in patients with advanced malignant disease was undertaken to evaluate drug toxicity (organ specificity, time course, predictability, reversibility, maximal tolerated dose), effectiveness, antigenicity and pharmacokinetics. TNF was administered as a test dose followed by daily i.v. infusions for 5 days, every 3 weeks (single i.v. infusion lasting 10 min, TNF dissolved in 50 ml 5% human… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Target-mediated drug disposition model for drugs that bind to more than one target

Journal of Pharmacokinetics and Pharmacodynamics • 2010
View 4 Excerpts
Highly Influenced

Acute O-GlcNAcylation prevents inflammation-induced vascular dysfunction.

American journal of physiology. Heart and circulatory physiology • 2012

Similar Papers

Loading similar papers…